Insight Molecular Diagnostics (IMDX) Return on Sales (2020 - 2026)

Insight Molecular Diagnostics (IMDX) has 7 years of Return on Sales data on file, last reported at 1.38% in Q1 2026.

• Quarterly Return on Sales fell 135.0% year-over-year to 1.38% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.04% (down 2.0% YoY) and the FY2025 annual result came in at 0.03%, up 4.0% from the prior year.
• Return on Sales declined to 1.38% in Q1 2026 per IMDX's latest filing, from 0.15% in the prior quarter.
• The five-year high for Return on Sales was 0.15% in Q4 2025, with the low at 1.38% in Q1 2026.
• Average Return on Sales over 5 years is 0.44%, with a median of 0.29% recorded in 2022.
• Year-over-year, Return on Sales jumped 118 bps in 2023 and tumbled 135 bps in 2026.
• Insight Molecular Diagnostics' Return on Sales stood at 1.2% in 2022, then soared by 98 bps to 0.02% in 2023, then surged by 607 bps to 0.1% in 2024, then jumped by 52 bps to 0.15% in 2025, then plunged by 1016 bps to 1.38% in 2026.
• Business Quant data shows IMDX's Return on Sales at 1.38% in Q1 2026, 0.15% in Q4 2025, and 0.42% in Q3 2025.